- Home
- ASMB
as 11-21-2024 11:31am EST
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 100.5M | IPO Year: | 2010 |
| Target Price: | $35.00 | AVG Volume (30 days): | 22.5K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.68 - $19.93 | Next Earning Date: | 11-07-2024 |
| Revenue: | $28,326,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 267.67% | Revenue Growth (next year): | 46.15% |
Stock Insider Trading Activity of Assembly Biosciences Inc. (ASMB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| White Nicole S | ASMB | Chief Manufacturing Officer | Nov 18 '24 | Sell | $16.29 | 40 | $651.60 | 11,871 | |
| Schornstein Alexander | ASMB | 10% Owner | Oct 8 '24 | Buy | $14.58 | 10,000 | $145,800.00 | 703,113 | |
| Okazaki Jason A | ASMB | CEO and President | Oct 3 '24 | Sell | $14.81 | 197 | $2,917.57 | 14,904 | |
| White Nicole S | ASMB | Chief Manufacturing Officer | Oct 3 '24 | Sell | $14.81 | 157 | $2,325.17 | 11,871 |
Latest Assembly Biosciences Inc. News
ASMB Breaking Stock News: Dive into ASMB Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates
Associated Press Finance
14 days ago
Assembly Biosciences: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 10/10/2024
Zacks
2 months ago
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Benzinga
2 months ago
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
GlobeNewswire
2 months ago
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
MT Newswires
2 months ago
Top Premarket Gainers
Compare ASMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASMB Assembly Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.